Our study evaluated systemic and bone marrow concentrations of APRIL and BAFF and their receptors in ET patients, and showed their significantly higher concentrations in peripheral blood, regardless of the presence of the JAK2(V617F) mutation. This evidence concerns the gene JAK2 and essential thrombocythemia.